Previous Close | 12.58 |
Open | 12.61 |
Bid | 12.50 x 0 |
Ask | 12.71 x 0 |
Day's Range | 12.58 - 12.61 |
52 Week Range | 9.27 - 15.43 |
Volume | |
Avg. Volume | 276 |
Market Cap | 340.917M |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and Regulatory Milestones, and Tiered Royalties Up to the Mid-Twenties ~ ~ Pro forma fourth quarter cash in excess of $55 million ~ ~ Managemen
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detai
Agreement pairs Norgine’s commercial expertise and leading European footprint with PEDMARQSI®, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors Fennec will receive €40 million in upfront and up to €210 million in additional commercial and regulatory milestones, and tiered royalties up to the mid-twenties Enhances Norgine’s commitment to bringing transformati